Researcher from Houston Methodist Hospital Discusses Findings in Herpes Zoster Virus (Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series).

A recent report from Houston Methodist Hospital discusses the development of shingles in a patient who had completed the recombinant varicella-zoster virus (VZV) vaccine series while taking tofacitinib, a medication used to treat autoimmune diseases. Shingles, caused by the reactivation of the VZV, is more common in older individuals and those with weakened immune systems. The researchers found that despite prior vaccination, the patient still developed shingles. The recombinant VZV vaccine is generally effective at reducing the risk of shingles, but this case highlights the need for further investigation in patients taking tofacitinib. [Extracted from the article]